Search results for "MARA"
showing 10 items of 343 documents
Efficacy of a fixed combination of ciclesonide and formoterol: the EXCITED-study.
2011
SummaryRecommended treatment for moderate to severe asthma is the combination of an inhaled corticosteroid and a long-acting beta2-agonist. The present study was designed to evaluate the efficacy of a newly developed fixed combination of ciclesonide and formoterol in comparison to the marketed fixed combination of fluticasone and salmeterol in patients with moderate asthma.This was a phase II, multi-centre, randomized, parallel-group, double-blind, double-dummy study. After a 2-week run-in period, 160 patients with moderate asthma were randomized to a 6-week treatment with ciclesonide/formoterol 320/9 μg bid (CIC/F) or fluticasone propionate/salmeterol 250/50 μg bid (FP/S), both delivered a…
Revising old principles of inhaled treatment in new fixed combinations for asthma.
2015
The major influencing factors on persistent asthma control are the selected treatment(s), the drug delivery route and patient's adherence to therapy, together with the influence of lifestyle (i.e. sedentary habit), comorbid conditions and specific asthma phenotypes. Inhaled corticosteroids (ICS) in combination with a long-acting β2-agonist (LABA) are the gold standard for management of persistent asthma, with maximal local targeting and minimal systemic side effects. Several innovative inhaler devices have been developed for effective local drug administration and good patient compliance to therapy. Recently, a new ICS/LABA fixed combination, formulated with fluticasone propionate (FP) and …
Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial …
2012
The inhaled corticosteroid fluticasone propionate (fluticasone) and the long-acting β₂ agonist formoterol fumarate (formoterol) have been combined in a single aerosol inhaler fluticasone/formoterol (flutiform(®)). This study compared the efficacy and safety of fluticasone/formoterol with the combination product budesonide/formoterol (Symbicort(®) Turbohaler(®)).A randomized, double-blind, double-dummy, multicenter, Phase 3 study comprising a 7- (± 3) day screening, 2-4-week run-in, and 12-week treatment periods. Patients aged ≥ 12 years with moderate to severe persistent asthma for ≥ 6 months before screening and forced expiratory volume in one second (FEV₁) 50-80% predicted and ≥ 15% rever…
Is the patient's baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen?
2011
Objective: Baseline inhaled corticosteroid (ICS) dose may be a factor for prescribers to consider when they select a budesonide/formoterol maintenance and reliever therapy regimen for symptomatic asthmatics. Methods: A 6-month randomized study compared two maintenance doses of budesonide/formoterol 160/4.5 µg, 1 × 2 and 2 × 2, plus as needed, in 8424 asthma patients with symptoms when treated with ICS ± an inhaled long-acting β2-agonist (LABA). In the total study population, 1339 (17%) were high-dose ICS (HD) users (≥1600 µg/day budesonide). This HD stratum was compared with the rest of the study population, divided into low-dose (LD; 400 µg/day) and medium-dose strata (MD; 401–1599 µg/day…
The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever u…
2012
Abstract Background Divergent strategies have emerged for the management of severe asthma. One strategy utilises high and fixed doses of maintenance treatment, usually inhaled corticosteroid/long-acting β2-agonist (ICS/LABA), supplemented by a short-acting β2-agonist (SABA) as needed. Alternatively, budesonide/formoterol is used as both maintenance and reliever therapy. The latter is superior to fixed-dose treatment in reducing severe exacerbations while achieving similar or better asthma control in other regards. Exacerbations may be reduced by the use of budesonide/formoterol as reliever medication during periods of unstable asthma. We examined the risk of a severe exacerbation in the per…
Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution
2022
Although bronchodilators are the cornerstone in chronic obstructive pulmonary disease (COPD) therapy, the treatment with a single-agent bronchodilator may not provide adequate symptoms control in COPD. The combination of drugs with different mechanisms of action may be more effective in inducing bronchodilation and preventing exacerbations, with a lower risk of side-effects in comparison with the increase of the dose of a single molecule. Several studies comparing the triple therapy with the association of long-acting ß2 agonist (LABA)/inhaled corticosteroid (ICS) or long-acting muscarinic antagonist (LAMA)/LABA reported improvement of lung function and quality of life. A significant reduc…
La penitencia del Amadís de Gaula en el Florisando de Páez de Ribera a la luz del folclore
2009
Este artículo examina cómo Páez de Ribera reconduce caminos ya hollados en el Amadís o las Sergas hacia lo religioso. La magia o la maravilla no desaparecen en el Florisando sino que se subliman y hacen trascendentes por el camino de los sufragios, penitencias y homilías propiciatorias. Amadís y su corte han quedado encantados por Urganda en los últimos capítulos de las Sergas. Páez de Ribera convierte este encantamiento en un purgatorio del que se sale no recurriendo a conjuros y otras ceremonias profanas, sino por la oración, la taumaturgia y la advocación milagrosa. Su postura no es pionera en la época.
Molecular markers indicate the phylogenetic identity of southern Brazilian sea asparagus: first record of Salicornia neei in Brazil
2019
Abstract Molecular phylogenetic analyses based on ETS, ITS and atpB - rbcL spacer sequences assessed the phylogenetic status of the southern Brazil sea asparagus species of the genus Salicornia (Salicornioideae, Amaranthaceae). Accessions of Patos Lagoon estuary (32° S) were obtained from wild plants and two pure line lineages, selected from contrasting prostrate (BTH1) and decumbent (BTH2) ecomorphotypes found locally. Patos Lagoon wild plants, BTH1 and BTH2 f4 progenies showed 100% identical sequences for the atpB - rbcL and ITS spacers, only two mutations for ETS. Comparison of the sequences of these three markers with GenBank records confirmed the identity of Brazilian accessions as Sal…
On the hybrid origin of the C2Salsola divaricata agg. (Amaranthaceae) from C3 and C4 parental lineages
2021
AbstractC2 photosynthesis is characterized by recapturing photorespiratory CO2 by RuBisCO in Kranz-like cells and is therefore physiologically intermediate between C3 and C4 photosynthesis. C2 can be interpreted as an evolutionary precursor of C4 and/or as the result of hybridization between a C3 and C4 lineage.We compared the expression of photosynthetic traits among populations of the Salsola divaricata agg. (C2) from humid subtropical to arid habitats on the coasts of the Canary Islands and Morocco and subjected them to salt and drought treatments. We screened for enhanced C4-like expression of traits related to habitat or treatment. We estimated species trees with a transcriptome datase…
Validation of the Marathon Motivation Scale in Chile
2021
The objective of this work was to validate the Marathon Motivation Scale (MOMS) for its application in the Chilean context. The study used a non-experimental, descriptive and transversal design. The sample was non-probability and intentional and was composed of 250 subjects (143 male and 104 female) runners who participated in the International Marathon of Viña del Mar with an average age of 29.8 (TD = 10.1) years. For the analysis of the data, an exploratory factorial analysis was carried out with free parameters, another one with seven factors fixed to the theoretical dimensions and a confirmatory factorial analysis with the items corresponding to the MOMS model. The validity and reliabil…